Rhythm Pharmaceuticals wins Japan approval for IMCIVREE in acquired hypothalamic obesity
Rhythm Pharmaceuticals says Japan’s MHLW approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity in Japan.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Rhythm wins Japan approval for Imcivree in acquired HO
Rhythm Pharmaceuticals says Japan's MHLW approves Imcivree (setmelanotide) for patients with acquired hypothalamic obesity, with launch in Japan expected by end of 2026 pending pricing.